Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dendreon’s Therapeutic Vaccine Provenge Gets “Complete Response” From FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA is requesting additional clinical data to support the efficacy of Dendreon’s BLA.

You may also be interested in...



PDUFA Cliffhanger: Will FDA End The Provenge Regulatory Saga?

FDA approval of Provenge for prostate cancer could come May 1, opening the door for the launch of the first cancer immunotherapy.

PDUFA Cliffhanger: Will FDA End The Provenge Regulatory Saga?

FDA approval of Provenge for prostate cancer could come May 1, opening the door for the launch of the first cancer immunotherapy.

Chart: Oncology: The Race Is On In HRPC; Sponsors Of Niche Oncologics Struggle

Sanofi-Aventis expects to complete a rolling NDA submission for its "home grown" novel taxoid Jevtana (cabazitaxel) by the end of the first quarter, Sanofi-Aventis Global Operations President Hanspeter Spek told a Feb. 10 earning call.

Related Content

Topics

UsernamePublicRestriction

Register

SC143162

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel